UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 1518, 2025

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-40439

27-0863354

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NMTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On ~~December~~August 2118, ~~2022~~2025, NeuroOne Medical Technologies Corporation ~~(the~~announced ~~“Company”)~~that ~~entered~~it ~~into~~has areceived ~~Capital~~U.S. onFood ~~Demand™~~and ~~Sales~~Drug ~~Agreement~~Administration 510(~~the “Sales Agreement”~~k) ~~with~~clearance ~~JonesTrading Institutional Services LLC (“JonesTrading”) pursuant~~ to ~~which~~market ~~the Company may sell from time to time shares of~~ its ~~common stock, par value $0.001 (the “Shares”) through any method permitted that is deemed an “at~~OneRF® Trigeminal ~~the~~Nerve ~~market~~Ablation ~~offering”~~System asfor ~~defined~~use in ~~Rule~~procedures ~~415(a)(4)~~to ~~under~~create ~~the~~radiofrequency ~~Securities~~lesions ~~Act~~for ~~of 1933, as amended, under which JonesTrading will act as sales agent (~~the ~~“ATM~~treatment ~~Program”).~~of ~~On August 15~~pain, ~~2025,~~or ~~the~~for ~~Company~~lesioning ~~filed~~nerve ~~an updated Prospectus Supplement (the “Prospectus”)~~tissue for ~~the~~functional ~~offer~~neurosurgical ~~and sale of up to $6~~procedures.~~75 million of Shares through JonesTrading pursuant to the Sales Agreement.~~

~~Honigman LLP, counsel to the Company, has issued an opinion relating to the Shares. A copy of such legal opinion is attached as Exhibit 5.~~1 ~~hereto.~~

The Shares will be sold pursuant to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdictionSIGNATURES

~~Item~~Pursuant ~~9.01~~to ~~Financial~~the ~~Statements~~requirements of ~~and~~the ~~Exhibits~~Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(d) Exhibits

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: August 18, 2025
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

Exhibit No.		Description
5.1		Opinion of Honigman LLP
104		Cover Page Interactive Data File (embedded in Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: August 15, 2025
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

Filing Compare · NEUROONE MEDICAL TECHNOLOGIES Corp